AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Revenue of AbbVie Inc. (ABBV)
Revenue in 2023 (TTM): $54.32 B
According to AbbVie Inc.'s latest financial reports the company's current revenue (TTM) is $54.32 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of AbbVie Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $54.32 B | $45.54 B | $26.36 B | $6.25 B | $4.86 B |
| 2022 | $58.05 B | $40.64 B | $31.42 B | $13.48 B | $11.84 B |
| 2021 | $56.2 B | $38.75 B | $28.28 B | $12.99 B | $11.54 B |
| 2020 | $45.8 B | $30.42 B | $21.15 B | $3.4 B | $4.62 B |
| 2019 | $33.27 B | $25.83 B | $16.26 B | $8.43 B | $7.88 B |
| 2018 | $32.75 B | $25.04 B | $13.69 B | $5.2 B | $5.69 B |
| 2017 | $28.22 B | $21.18 B | $11.77 B | $7.73 B | $5.31 B |
| 2016 | $25.64 B | $19.81 B | $10.81 B | $7.88 B | $5.95 B |
| 2015 | $22.86 B | $18.36 B | $9.69 B | $6.65 B | $5.14 B |
| 2014 | $19.96 B | $15.53 B | $6.29 B | $2.37 B | $1.77 B |
| 2013 | $18.79 B | $14.21 B | $6.91 B | $5.33 B | $4.13 B |
| 2012 | $18.38 B | $13.87 B | $6.98 B | $5.73 B | $5.28 B |
| 2011 | $17.44 B | $12.8 B | $4.94 B | $3.67 B | $3.43 B |
| 2010 | $15.64 B | $11.35 B | $6.02 B | $4.84 B | $4.18 B |
| 2009 | $14.21 B | $10.16 B | $6.65 B | $5.95 B | $4.64 B |